newsfilter
← Latest News
GlobeNewswire·

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease

- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging